150 related articles for article (PubMed ID: 31569615)
1. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
[TBL] [Abstract][Full Text] [Related]
3. Effects of pharmacological primary cilium disturbance in the context of in vitro 2D and 3D malignant pleura mesothelioma.
Jagirdar RM; Pitaraki E; Kotsiou OS; Rouka E; Sinis SI; Varsamas C; Marnas P; Stergiopoulou E; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Biochem Biophys Res Commun; 2023 Apr; 654():128-135. PubMed ID: 36907140
[TBL] [Abstract][Full Text] [Related]
4. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.
Jagirdar RM; Apostolidou E; Molyvdas PA; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG
Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(6):L489-95. PubMed ID: 26773069
[TBL] [Abstract][Full Text] [Related]
5. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
6. Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro.
Jagirdar RM; Papazoglou ED; Pitaraki E; Kouliou OA; Rouka E; Giannakou L; Giannopoulos S; Sinis SI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):543-552. PubMed ID: 33336399
[TBL] [Abstract][Full Text] [Related]
7. Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality.
Katkova LE; Baturina GS; Bondar AA; Jagirdar RM; Hatzoglou C; Gourgoulianis KI; Solenov EI; Zarogiannis SG
Cell Physiol Biochem; 2019; 52(4):869-878. PubMed ID: 30958661
[TBL] [Abstract][Full Text] [Related]
8. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
9. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
10. Changes in expression of mesothelial BBS genes in 2D and 3D after lithium chloride and ammonium sulphate induction of primary cilium disturbance: a pilot study.
Rouka E; Jagirdar RM; Sarrigeorgiou I; Pitaraki E; Sinis SI; Varsamas C; Papazoglou ED; Kotsiou OS; Lymberi P; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Pharmacol Rep; 2023 Oct; 75(5):1230-1239. PubMed ID: 37542187
[TBL] [Abstract][Full Text] [Related]
11. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
12. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
Cioce M; Canino C; Pass H; Blandino G; Strano S; Fazio VM
J Exp Clin Cancer Res; 2021 Nov; 40(1):344. PubMed ID: 34727953
[TBL] [Abstract][Full Text] [Related]
13. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
15. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
17. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in malignant pleural mesothelioma.
Gatzemeier U
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
[TBL] [Abstract][Full Text] [Related]
19. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
20. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.
Sun R; Tanino R; Tong X; Haque EF; Amano Y; Isobe T; Tsubata Y
Transl Lung Cancer Res; 2022 Apr; 11(4):543-559. PubMed ID: 35529797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
